immun
rightli
regard
one
great
medic
success
past
two
hundr
year
particularli
centuri
develop
countri
decad
immun
programm
led
elimin
smallpox
polio
control
near
elimin
oncecommon
often
debilit
even
lifethreaten
diseas
measl
mump
rubella
diptheria
tetanu
despit
view
poor
rel
tradit
drug
develop
vaccin
market
estim
us
billion
fig
project
annual
growth
rate
recent
media
attent
surround
new
emerg
infect
west
nile
viru
sever
acut
respiratori
syndrom
sar
monkeypox
increas
interest
develop
new
vaccin
potenti
lethal
pathogen
ad
fear
known
unknown
pathogen
could
use
bioweapon
renew
research
interest
diseas
smallpox
anthrax
plagu
although
new
concept
use
bacteria
virus
bioweapon
becom
greater
topic
convers
follow
anthrax
attack
unit
state
sinc
mani
govern
acceler
effort
develop
produc
stockpil
drug
vaccin
number
pathogen
potenti
use
bioweapon
includ
bacillu
anthraci
anthrax
clostridium
botulinum
botul
yersinia
pesti
plagu
francisella
tularensi
tularemia
variola
smallpox
hantaviru
hantaviru
pulmonari
syndrom
part
effort
presid
bush
project
bioshield
bill
invest
us
billion
next
decad
research
new
prevent
treatment
includ
privat
public
effort
unit
state
collabor
research
bodi
around
world
infecti
agent
smallpox
effect
vaccin
alreadi
exist
help
erad
diseas
global
last
known
case
smallpox
report
despit
smallpox
still
pose
signific
threat
bioweapon
highli
contagi
countri
immun
programm
ceas
result
larg
pool
unprotect
peopl
seriou
side
effect
exist
smallpox
vaccin
dryvax
wyeth
threat
new
virul
form
smallpox
mean
still
need
new
safer
version
vaccin
new
strategi
includ
use
live
attenu
vaccinia
viru
modifi
vaccinia
ankara
mvabn
bavarian
tbcmva
therion
phase
trial
altern
manufactur
vaccinia
vaccin
acambi
ccsv
dynport
phase
ii
trial
respect
recent
outbreak
sar
remind
us
new
virul
virus
suddenli
emerg
anytim
spread
rapidli
around
globe
world
health
organ
estim
peopl
infect
sar
countri
kill
estim
peoplealthough
nearli
scale
influenza
pandem
sar
remain
menac
global
public
health
especi
turn
season
diseas
follow
first
report
case
sar
late
februari
health
agenc
quickli
realiz
deal
one
typic
respiratori
virus
caus
diseas
pneumonia
flu
exampl
respiratori
syncyti
viru
influenza
viru
instead
new
virul
strain
coronaviru
often
associ
sever
patholog
fortun
sar
epidem
short
live
still
place
consider
strain
health
system
mani
affect
countri
threat
remain
still
great
need
sar
vaccin
prevent
loss
life
potenti
larger
scale
end
larg
number
public
privat
initi
underway
develop
sar
vaccin
exampl
nation
institut
health
merck
genvec
avant
immunotherapeut
activ
area
although
even
optimist
estim
vaccin
still
least
five
year
away
hunt
hiv
vaccin
arguabl
one
urgent
task
time
million
dollar
spent
tri
understand
everi
aspect
viru
role
pathogenesi
mani
antiretrovir
avail
treat
hiv
side
effect
associ
resist
issu
none
offer
cure
instead
prolong
time
onset
aid
addit
drug
exert
heavi
financi
toll
develop
countri
often
unabl
bear
hope
develop
effect
hiv
vaccin
could
help
eas
econom
burden
unfortun
hiv
like
malaria
tuberculosi
turn
tricki
develop
effect
vaccin
high
degre
antigen
variabl
exist
among
hiv
strain
exampl
recent
failur
subunit
vaccin
aidsvax
bb
vaxgen
advanc
hiv
vaccin
develop
howev
result
dampen
research
effort
field
contrari
seen
explos
activ
past
year
present
phase
ii
iii
trial
ongo
involv
varieti
differ
strategi
includ
use
complex
subunit
vaccin
exampl
oligomer
protein
recombin
viral
vector
includ
attenu
adenoviru
canarypox
modifi
vaccinia
ankara
bcg
semliki
forest
viru
primeboost
strategi
dna
vaccin
design
protect
patient
wherea
other
attempt
strengthen
immun
respons
prolong
progress
aid
tradit
vaccin
continu
gener
major
us
billion
vaccin
sale
year
fig
although
believ
futur
growth
driven
new
vaccin
includ
improv
deliveri
mechan
exampl
medimmun
intranas
flumist
well
vaccin
emerg
diseas
pathogen
pose
threat
possibl
bioweapon
tabl
infecti
agent
hiv
present
affect
estim
million
peopl
around
globe
highlight
great
need
futur
vaccin
wherea
viru
also
shown
us
signific
difficulti
exampl
antigen
variat
must
overcom
truli
global
vaccin
develop
report
prepar
bear
stearn
co
inc
bear
stearn
intern
limit
bear
stearn
asia
limit
togeth
affili
bear
stearn
indic
cover
page
hereof
report
adopt
approv
distribut
unit
state
bear
stearn
co
inc
recipi
public
unit
state
order
secur
refer
herein
place
bear
stearn
co
inc
report
approv
public
unit
kingdom
bear
stearn
intern
limit
regul
unit
kingdom
financi
servic
author
privat
custom
uk
contact
bear
stearn
intern
limit
repres
invest
concern
report
distribut
hong
kong
bear
stearn
asia
limit
regul
secur
futur
commiss
hong
kong
addit
inform
avail
upon
request
bear
stearn
employe
offic
director
deal
princip
transact
involv
secur
refer
herein
option
instrument
relat
thereto
includ
transact
contrari
recommend
contain
herein
bear
stearn
employe
may
also
engag
transact
issuer
identifi
herein
public
constitut
offer
solicit
transact
secur
refer
herein
recommend
contain
herein
may
suitabl
investor
although
inform
contain
subject
report
obtain
sourc
believ
reliabl
accuraci
complet
guarante
public
recommend
contain
herein
speak
date
hereof
subject
chang
without
notic
bear
stearn
affili
compani
employe
shall
oblig
updat
amend
inform
contain
herein
public
furnish
inform
purpos
condit
form
primari
basi
invest
decis
investor
must
make
determin
appropri
invest
secur
refer
herein
base
legal
tax
account
consider
applic
investor
invest
strategi
virtu
public
none
bear
stearn
employe
shall
respons
invest
decis
report
may
reproduc
distribut
publish
without
prior
consent
bear
stearn
right
reserv
bear
stearn
report
may
discuss
numer
secur
may
qualifi
sale
certain
state
may
therefor
offer
investor
state
outperform
stock
project
outperform
analyst
industri
coverag
univers
next
month
peer
perform
p
stock
project
perform
approxim
line
analyst
industri
coverag
univers
next
month
underperform
u
stock
project
underperform
analyst
industri
coverag
univers
next
month
rate
sector
vs
region
broader
market
index
market
overweight
mo
expect
industri
perform
better
primari
market
index
region
next
month
market
weight
mw
expect
industri
perform
approxim
line
primari
market
index
region
next
month
market
underweight
mu
expect
industri
underperform
primari
market
index
region
next
month
cost
expens
equiti
research
includ
compens
analyst
prepar
report
paid
firm
total
revenu
portion
gener
invest
bank
activ
import
disclosur
inform
regard
compani
report
pleas
contact
regist
repres
write
uzi
rosha
equiti
research
complianc
bear
stearn
co
inc
madison
avenu
new
york
ny
